antibodies
Pistoia Alliance publishes first best-practice framework for ethical social media use in drug development
The Alliance calls for funding and expertise for the next phase of its social media project, marking its first direct engagement with oncology, rare disease and cardiology patients
Eli Lilly to expand long-standing Purdue University partnership with $250m investment
The alliance will aim to bring medicines to patients faster using advanced technologies
AstraZeneca announces $2.5bn investment in China to boost R&D capabilities
The funds will go towards a new global research and development centre in Beijing’s BioPark
Chiesi Group invests €400m to establish biotech centre of excellence in Italy
The facility is dedicated to developing and producing monoclonal antibodies, enzymes and other proteins
Eli Lilly announces new $4.5bn US site for manufacturing and drug development
The Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers
Answering some of Pharma’s big questions to drive brand strategies
By James Aird and Zoë van Helmond
FDA establishes rare disease innovation hub to accelerate treatment development
More than 30 million people in the US are currently affected by a rare disease
Experts issue call for new ‘toolbox’ to simplify early-phase clinical trial regulation in UK
The article outlines several recommendations to help improve early-phase clinical trials
Sanofi, Formation Bio and OpenAI announce AI collaboration to accelerate drug development
The companies will combine data, software and tuned models to bring new medicines to patients more efficiently
AI drug discovery biotech Xaira Therapeutics launches with over $1bn in committed funding
The company combines machine learning, data generation and therapeutic product development
Date set for EU antitrust regulators to decide on Pfizer’s $43bn Seagen acquisition
The proposed transaction would mark a significant boost to the US pharma’s oncology pipeline